Clifford Bechtold
Compliance Officer chez BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Profil
M. Clifford Bechtold est directeur de l'exploitation chez Biohaven Pharmaceutical Holding Co. Ltd. M. Bechtold était auparavant employé comme vice-président des opérations stratégiques chez Adnexus et comme directeur du personnel chez Bristol Myers Squibb Co. Il a obtenu son diplôme de premier cycle à l'université d'État du Dakota du Sud et un diplôme d'études supérieures à la faculté de médecine de l'université Creighton.
Postes actifs de Clifford Bechtold
| Sociétés | Poste | Début |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Compliance Officer | - |
| BIOHAVEN LTD. | Compliance Officer | - |
Anciens postes connus de Clifford Bechtold
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2013 |
Adnexus
 Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/10/2011 |
Formation de Clifford Bechtold
| South Dakota State University | Undergraduate Degree |
| The Creighton University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Health Technology |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
